Abstract
DP-VPA (SPD 421) 1 1 Licensing partner: Shire Pharmaceuticals Group plc. is a new compound, where valproic acid is chemically bound to lecithin. It is a novel prodrug of valproic acid with targeted action for the treatment of epilepsy. RP-HPLC stability indicating method has been developed for this and relative compounds. Versatile detection techniques could be used with these LC procedures. The absence of non-volatile components in the mobile phase allows running the method with evaporative light scattering and MS-detectors. The method appeared to be sensitive, selective, reproducible, and stability indicating. It could be easily upgraded to bioanalytical procedures applying LC-MS technique. The method could be used as ‘generic’ for numerous compounds having similar design of the molecules, such as lecithin-based derivatives of diclofenac, naproxen, ibuprofen, and indometacin. The strategy of HPLC method development for polar lipids is discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
